Marshall Wace LLP grew its holdings in Humana Inc (NYSE:HUM) by 314.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 80,138 shares of the insurance provider’s stock after acquiring an additional 60,809 shares during the period. Marshall Wace LLP’s holdings in Humana were worth $27,128,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in the company. EP Wealth Advisors LLC boosted its holdings in shares of Humana by 21.4% in the 3rd quarter. EP Wealth Advisors LLC now owns 929 shares of the insurance provider’s stock valued at $314,000 after acquiring an additional 164 shares during the last quarter. Financial Gravity Wealth Inc. boosted its holdings in shares of Humana by 41.9% in the 3rd quarter. Financial Gravity Wealth Inc. now owns 562 shares of the insurance provider’s stock valued at $179,000 after acquiring an additional 166 shares during the last quarter. Carillon Tower Advisers Inc. boosted its holdings in shares of Humana by 0.6% in the 3rd quarter. Carillon Tower Advisers Inc. now owns 27,160 shares of the insurance provider’s stock valued at $9,194,000 after acquiring an additional 168 shares during the last quarter. San Francisco Sentry Investment Group CA boosted its holdings in shares of Humana by 46.9% in the 3rd quarter. San Francisco Sentry Investment Group CA now owns 598 shares of the insurance provider’s stock valued at $203,000 after acquiring an additional 191 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its holdings in shares of Humana by 1.7% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,901 shares of the insurance provider’s stock valued at $3,541,000 after acquiring an additional 197 shares during the last quarter. 92.90% of the stock is currently owned by institutional investors and hedge funds.
NYSE:HUM opened at $306.00 on Friday. The company has a quick ratio of 1.68, a current ratio of 1.68 and a debt-to-equity ratio of 0.45. The firm has a market cap of $43.39 billion, a price-to-earnings ratio of 26.13, a P/E/G ratio of 1.50 and a beta of 0.99. Humana Inc has a fifty-two week low of $242.00 and a fifty-two week high of $355.88.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.29 by $0.29. The company had revenue of $14.21 billion during the quarter, compared to analysts’ expectations of $13.97 billion. Humana had a net margin of 2.70% and a return on equity of 19.10%. During the same period in the prior year, the business posted $3.39 earnings per share. As a group, equities research analysts predict that Humana Inc will post 14.43 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 25th. Shareholders of record on Monday, December 31st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date of this dividend is Friday, December 28th. Humana’s dividend payout ratio is presently 11.96%.
HUM has been the topic of several recent research reports. Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $377.00 price objective on the stock in a report on Thursday, October 4th. Morgan Stanley increased their price target on shares of Humana from $400.00 to $418.00 and gave the stock a “buy” rating in a report on Thursday, November 8th. Credit Suisse Group increased their price target on shares of Humana from $350.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, September 4th. Bank of America increased their price target on shares of Humana from $400.00 to $415.00 and gave the stock a “buy” rating in a report on Thursday, November 8th. Finally, Cowen began coverage on shares of Humana in a report on Monday, September 17th. They set a “market perform” rating and a $372.00 price target on the stock. Seven equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Humana currently has a consensus rating of “Buy” and a consensus price target of $352.10.
In other Humana news, CEO Bruce D. Broussard sold 18,000 shares of the company’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the completion of the transaction, the chief executive officer now directly owns 71,085 shares in the company, valued at $23,362,796.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Roy A. Beveridge sold 4,622 shares of the company’s stock in a transaction on Thursday, November 8th. The stock was sold at an average price of $341.06, for a total transaction of $1,576,379.32. Following the transaction, the insider now owns 10,621 shares of the company’s stock, valued at $3,622,398.26. The disclosure for this sale can be found here. Corporate insiders own 0.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/12/08/marshall-wace-llp-acquires-60809-shares-of-humana-inc-hum.html.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Recommended Story: Outstanding Shares
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.